Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Quick facts
Phase 3 pipeline
- Lenalidomide, Dexamethasone, PBSCT · Oncology
Lenalidomide enhances immune cell activity and promotes apoptosis of myeloma cells, while dexamethasone provides anti-inflammatory and anti-tumor effects, followed by peripheral blood stem cell transplantation to restore bone marrow function.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH portfolio CI brief
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH pipeline updates RSS
Frequently asked questions about Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
What is Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH's pipeline?
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Lenalidomide, Dexamethasone, PBSCT.
Related
- Sector hub: All tracked pharma companies